Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
37.66
-0.22 (-0.58%)
Real-time:   12:37PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.33 - 37.94
52 week 30.18 - 51.31
Open 37.90
Vol / Avg. 76,750.00/505,133.00
Mkt cap 2.09B
P/E     -
Div/yield     -
EPS -0.74
Shares 55.41M
Beta 0.76
Inst. own 114%
Aug 4, 2014
Q2 2014 Insulet Corporation Earnings Release (Estimated) Add to calendar
Jun 10, 2014
Insulet Corporation at William Blair & Company LLC Growth Stock Conference
Jun 2, 2014
Insulet Corporation at Jefferies Global Healthcare Conference
May 15, 2014
Insulet Corporation at Bank of America Merrill Lynch Health Care Conference
May 7, 2014
Q1 2014 Insulet Corporation Earnings Conference Call
May 7, 2014
Q1 2014 Insulet Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -8.88% -18.20%
Operating margin -2.73% -11.79%
EBITD margin - -7.01%
Return on average assets -8.55% -18.51%
Return on average equity -19.95% -53.30%
Employees 478 -
CDP Score - -

Address

9 OAK PARK DRIVE
BEDFORD, MA 01730
United States - Map
+1-781-4575000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (the OmniPod System). The OmniPod System is an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the Company's handheld, wireless Personal Diabetes Manager (PDM). The OmniPod Insulin Management System is designed to provide people with insulin-dependent diabetes with a diabetes management solution which provides lifestyle and other benefits and to expand the use of continuous subcutaneous insulin infusion (CSII) therapy. The OmniPod operates up to 72 hours (but no more than 80 hours) after it is activated.

Officers and directors

Duane M. DeSisto President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Brian K. Roberts CPA Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
William Patrick Ryan Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
R. Anthony Anthony Diehl Esq. General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Peter Devlin Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
Sally W. Crawford Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Charles T. Liamos Director
Age: 54
Bio & Compensation  - Reuters
John A. Fallon M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Daniel J. Levangie Independent Director
Age: 63
Bio & Compensation  - Reuters
Steven T. Sobieski Independent Director
Age: 57
Bio & Compensation  - Reuters